Compare Vanguard Total Bond Market Index Fund ETF (BND) vs Gilead Sciences, Inc. (GILD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vanguard Total Bond Market Index Fund ETF vs Gilead Sciences, Inc. — how do they compare? Vanguard Total Bond Market Index Fund ETF trades at $72.7, while Gilead Sciences, Inc. trades at $129.78 (market cap $161.45B). The key difference: Gilead Sciences, Inc. pays a 2.52% dividend while Vanguard Total Bond Market Index Fund ETF pays none, and Gilead Sciences, Inc. is trading nearer its 52-week high, Vanguard Total Bond Market Index Fund ETF nearer its low. Which is the better fit depends on your goals.
| BND | GILD | |
|---|---|---|
52-Week High | $75.17 | $155.80 |
52-Week Low | $72.45 | $108.22 |
Market Cap | — | $161.45B |
Sector | — | Health |
Enterprise Value | — | $175.98B |
Dividend Yield | — | 2.52% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BND trades at $72.50, down 0.37% with a bearish technical outlook showing 19 sell signals versus 4 buy signals. The ETF faces pressure from rising interest rate expectations, though recent dividend payments of $0.24-$0.25 provide income stability. Fixed income ETFs have seen renewed investor interest with $100 billion flowing into cash ETFs recently, indicating defensive positioning.
The bond ETF faces headwinds from potential Fed rate hikes but offers diversification benefits. Key risks include interest rate sensitivity and competition from higher-yielding alternatives. Long-term investors may find value in BND's broad market exposure and low costs despite near-term technical weakness.
Gilead Sciences (GILD) trades at $131.40, up 1.21% with strong technical momentum and bullish moving averages. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA approvals for Trodelvy in metastatic triple-negative breast cancer and ongoing Ebola antiviral trials highlight pipeline strength. Analyst consensus remains strongly positive with a $152.83 price target.
GILD presents a compelling investment case with strong profitability, expanding oncology portfolio, and 67% analyst buy ratings. Key risks include patent expirations on HIV drugs and volatile cash flow trends. The stock offers 16% upside to consensus target with dividend support, though investors should monitor pipeline execution and generic competition timelines.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Vanguard Total Bond Market Index Fund ETF
This index measures the performance of a wide spectrum of public, investment-grade, taxable, fixed income securities in the US, including government, corporate, and international dollar-denominated bonds, as well as mortgage-backed and asset-backed securities-all with maturities of more than 1 year. All of the fund's investments will be selected through the sampling process, and at least 80% of its assets will be invested in bonds held in the index.
Read more on BND →About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →
